Literature DB >> 23626565

Are steroids a beneficial adjunctive therapy in the immunosuppressed patient with herpes simplex virus encephalitis?

Karlo J Lizarraga1, Lucien C Alexandre, Ciro Ramos-Estebanez, Amedeo Merenda.   

Abstract

Few reports describe the reactivation of latent herpes simplex virus causing encephalitis (HSVE) in patients undergoing brain radiation therapy and a concomitant steroid regimen. The role for steroid use in the treatment of patients with HSVE has not been fully elucidated. We report the case of a female patient immunosuppressed by steroids and brain radiation who developed HSVE and responded to acyclovir and dexamethasone.

Entities:  

Keywords:  Corticosteroids; Herpes simplex virus encephalitis; Immunosuppression

Year:  2013        PMID: 23626565      PMCID: PMC3635685          DOI: 10.1159/000350572

Source DB:  PubMed          Journal:  Case Rep Neurol        ISSN: 1662-680X


Introduction

Herpes simplex virus (HSV) is the most common cause of sporadic encephalitis in humans [1]. HSV encephalitis (HSVE) may be caused by a primary infection or reactivation of a latent infection of sensory ganglia or frontotemporal cortices. HSV reactivation from the trigeminal ganglion or brain parenchyma might be caused by immunosuppression due to the concomitant use of corticosteroids and brain radiotherapy [2]. Typical HSVE presentation includes a rapid onset of fever and impaired consciousness, often accompanied by focal neurologic signs and seizures. Acyclovir is the treatment of choice for it significantly reduces mortality. Unfortunately, complete recovery occurs only in half of the patients [3]. We report a case in which the adjunctive use of steroids lead to a significant improvement in an immunosuppressed patient with HSVE.

Clinical Presentation

A 32-year-old, right-handed, female patient with a right glomus jugulare paraganglioma was undergoing stereotactic radiation therapy (including the trigeminal ganglion in Meckel's cave) (fig. 1) and received oral dexamethasone (16 mg daily). After completing an 11-week regimen, dexamethasone was tapered off and discontinued.
Fig. 1

The patient's radiation therapy plan involving the left trigeminal ganglion (Meckel's cave), frontal and temporal cortices.

The following week, she began having emotional lability and difficulties with short-term memory. For the next 3 weeks, her family noted increased irritability, difficulty in following commands and focusing on tasks. Eventually, she was febrile and had a 5-min episode characterized by the inability to answer simple questions, lip smacking, chewing and wringing of the bed sheets. Once admitted, she was awake, alert and only oriented to person. She followed axial and appendicular commands. Stereotyped movements of her hands and mouth were noted. Examination revealed that the cranial motor nerves were intact, and there were no meningeal signs. A CT scan showed a new focal hypodensity within the right temporal lobe (fig. 2a), but the paraganglioma remained unchanged. Empirical levetiracetam, vancomycin, cefepime, ampicillin and acyclovir were started. Lumbar puncture showed 120 lymphocytes/mm3, a glucose level of 52 mg% and a protein level of 115 mg%. Gram stain was negative but HSV-1 PCR of her cerebrospinal fluid returned positive.
Fig. 2

Head CT, axial view. a A focal hypodensity within the right temporal lobe is observed on admission. b On the fifth day after admission, bilateral worsening of the hypodensities in the orbital frontal, cingular, insular and temporal regions in spite of isolated acyclovir treatment occurred.

The next day, she became lethargic, and electroencephalography showed generalized background delta slowing. An MRI scan demonstrated bilateral restricted diffusion, a high FLAIR signal and T1 postcontrast enhancement in her mesial temporal, orbitofrontal, cingular and insular lobes. Until the fifth day after admission, the patient remained febrile and could not follow commands. A CT scan showed larger bilateral hypodensities in the orbital frontal, temporal, insular and cingular regions (fig. 2b). Daily dexamethasone 40 mg iv was added to her acyclovir regimen. Seventy-two hours later, the patient was afebrile and followed axial commands. Once she had completed 5 days of steroid and 21 days of acyclovir treatment, she was alert, oriented to person and place, following axial and appendicular commands and producing simple sentences.

Discussion

Clinicians are hesitant to use steroids during HSVE due to the concern of immunosuppression. Indeed, several observations argue for a reactivation of latent HSV in patients receiving radiation and corticosteroids, leading to HSVE [2]. Furthermore, the morbidity of HSV has mostly been associated with its reactivation, which is enhanced by a steroid-impaired immunological response [4]. However, this evidence stems from nonneural culture and tissue studies. Besides, animal experiments showed that steroid therapy does not correlate with HSV dissemination or viral load [5]. Finally, even if the viral load were enhanced by steroid therapy, other quantitative viral markers do not correlate with radiological changes [6] or clinical outcomes [7]. Corticosteroids may be beneficial in HSVE for decreasing the activation of several inflammatory pathways [8]. Actually, adjunctive corticosteroid administration has been advantageous in the treatment of other infectious diseases with exaggerated inflammatory responses (i.e. bacterial meningitis [9], tuberculous meningitis [10] or herpetic keratitis [11]). In the case of HSVE, animal models [5, 8] and human reports [12] support the adjunctive use of corticosteroids. Steroids are used in HSVE mostly when there is evidence of progression in spite of acyclovir treatment (fig. 2) [12]. We hope that the GACHE trial [13] will address the value of corticosteroids in HSVE.
  13 in total

1.  Herpes simplex virus encephalitis: chronic progressive cerebral magnetic resonance imaging abnormalities in patients despite good clinical recovery.

Authors:  U K Meyding-Lamadé; W R Lamadé; B T Wildemann; K Sartor; W Hacke
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

2.  Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome.

Authors:  N McGrath; N E Anderson; M C Croxson; K F Powell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

3.  Acute and long-term alteration of chemokine mRNA expression after anti-viral and anti-inflammatory treatment in herpes simplex virus encephalitis.

Authors:  Johann Sellner; Florian Dvorak; Yilin Zhou; Jürgen Haas; Roland Kehm; Brigitte Wildemann; Uta Meyding-Lamadè
Journal:  Neurosci Lett       Date:  2004-11-30       Impact factor: 3.046

4.  Dexamethasone in adults with bacterial meningitis.

Authors:  Jan de Gans; Diederik van de Beek
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

5.  Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis.

Authors:  B Wildemann; K Ehrhart; B Storch-Hagenlocher; U Meyding-Lamadé; S Steinvorth; W Hacke; J Haas
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis.

Authors:  K A Thompson; W W Blessing; S L Wesselingh
Journal:  J Neurovirol       Date:  2000-02       Impact factor: 2.643

7.  Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.

Authors:  Guy E Thwaites; Duc Bang Nguyen; Huy Dung Nguyen; Thi Quy Hoang; Thi Tuong Oanh Do; Thi Cam Thoa Nguyen; Quang Hien Nguyen; Tri Thuc Nguyen; Ngoc Hai Nguyen; Thi Ngoc Lan Nguyen; Ngoc Lan Nguyen; Hong Duc Nguyen; Ngoc Tuan Vu; Huu Hiep Cao; Thi Hong Chau Tran; Phuong Mai Pham; Thi Dung Nguyen; Kasia Stepniewska; Nicholas J White; Tinh Hien Tran; Jeremy J Farrar
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

8.  Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis.

Authors:  S Kamei; T Sekizawa; H Shiota; T Mizutani; Y Itoyama; T Takasu; T Morishima; K Hirayanagi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

9.  Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis.

Authors:  K R Wilhelmus; L Gee; W W Hauck; N Kurinij; C R Dawson; D B Jones; B A Barron; H E Kaufman; J Sugar; R A Hyndiuk
Journal:  Ophthalmology       Date:  1994-12       Impact factor: 12.079

10.  Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933].

Authors:  Francisco Martinez-Torres; Sanjay Menon; Maria Pritsch; Norbert Victor; Ekkehart Jenetzky; Katrin Jensen; Eva Schielke; Erich Schmutzhard; Jan de Gans; Chin-Hee Chung; Steffen Luntz; Werner Hacke; Uta Meyding-Lamadé
Journal:  BMC Neurol       Date:  2008-10-29       Impact factor: 2.474

View more
  10 in total

Review 1.  Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Clin Microbiol Rev       Date:  2020-02-12       Impact factor: 26.132

Review 2.  Herpes Simplex Encephalitis: an Update.

Authors:  John W Gnann; Richard J Whitley
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

3.  Herpes simplex encephalitis in patients receiving chemotherapy and whole-brain radiation therapy.

Authors:  Nir Hersh; Israel Steiner; Tali Siegal; Felix Benninger
Journal:  J Neurovirol       Date:  2021-09-21       Impact factor: 2.643

Review 4.  Update on herpes virus infections of the nervous system.

Authors:  Israel Steiner; Felix Benninger
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

5.  Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication.

Authors:  Yong Liang; Kaiting Yang; Jingya Guo; Joanna Wroblewska; Yang-Xin Fu; Hua Peng
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

6.  Herpes simplex encephalitis as a complication of whole-brain radiotherapy: a case report and review of the literature.

Authors:  David J Sermer; Jamie L Woodley; Christian A Thomas; Jacquelyn A Hedlund
Journal:  Case Rep Oncol       Date:  2014-11-21

7.  Genome-wide expression datasets of anti-VEGF and dexamethasone treatment of angiogenesis in the rat cornea.

Authors:  Anthony Mukwaya; Pierfrancesco Mirabelli; Anton Lennikov; Maria Xeroudaki; Mira Schaupper; Beatrice Peebo; Neil Lagali
Journal:  Sci Data       Date:  2017-08-15       Impact factor: 6.444

8.  The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  U Meyding-Lamadé; C Jacobi; F Martinez-Torres; T Lenhard; B Kress; M Kieser; C Klose; K Einhäupl; J Bösel; M-B Mackert; V Homberg; C Koennecke; G Weißheit; D Claus; B Kieseier; J Bardutzky; T Neumann-Haefelin; M W Lorenz; H Steinmetz; C Gerloff; D Schneider; A Grau; M Klein; R Dziewas; U Bogdahn; W Jakob; R Linker; K Fuchs; A Sander; S Luntz; T Hoppe-Tichy; D F Hanley; R von Kummer; E Craemer
Journal:  Neurol Res Pract       Date:  2019-09-12

9.  Brain microvascular endothelial-astrocyte cell responses following Japanese encephalitis virus infection in an in vitro human blood-brain barrier model.

Authors:  Adjanie Patabendige; Benedict D Michael; Alister G Craig; Tom Solomon
Journal:  Mol Cell Neurosci       Date:  2018-04-07       Impact factor: 4.314

10.  Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis.

Authors:  Thomas Whitfield; Cristina Fernandez; Kelly Davies; Sylviane Defres; Michael Griffiths; Cory Hooper; Rebecca Tangney; Girvan Burnside; Anna Rosala-Hallas; Perry Moore; Kumar Das; Mark Zuckerman; Laura Parkes; Simon Keller; Neil Roberts; Ava Easton; Saber Touati; Rachel Kneen; J P Stahl; Tom Solomon
Journal:  BMJ Open       Date:  2021-07-22       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.